A World’s First Multi-Layered Mechanism of Action

Unlike current antibiotics, which are typically naturally occurring in certain fungi and soil bacteria, Recce’s anti-infectives are wholly synthetic and based on a patented polymeric structure and have been designed to overcome resistance. Traditional antibiotics inhibit a single target such as bacterial gyrase enzymes, cell wall biosynthetic enzymes, or enzymes required for DNA replication during bacterial cell division. They operate on a ‘lock and key’ mechanism and therefore only bind to a few active sites on the bacterial target. However, if a mutation is introduced into the target site, then the antibiotic will cease to be effective.


RECCE® 327 may be administered for intravenous, topical, nasal, oral and inhaled use. RECCE® 327’s universal mechanism of action has a patented ability to continuously kill bacteria without tendency for the emergence of resistance, even with repeated use, indicating a unique ability to combat antibiotic resistant superbugs

R327 rapidly and irreversibly shuts down cellular energetics (adenosine triphosphate (ATP) production) – primary MoA

R327 affects the assembly of bacterial cell division complex, components that require cellular energy to remain assembled, confirming its ability to disrupt cellular bioenergetics

R327 results in the decreased formation of the bacterial cell division complex into ring-like structures (Z-rings) in a concentration dependent manner

R327 permeabilises the cell membrane/alters the integrity of the outer membrane of Escherichia coli (E. coli) cells – intended activity without toxicity

At higher concentrations and subsequent to ATP shut down cell lysis can occur as a further MoA (bacterial bursting due to their uniquely high internal pressures)

R327 rapidly and irreversibly bactericidal to slow-growing, quiescent or stationary phase
E. coli cells in addition to actively dividing E.coli cells.

Within a minute, the highest concentration of R327 used, 5x minimum inhibitory concentration (MIC), was observed to reduce viable cell counts reported as cell forming units per millilitre of culture (CFU/ml) 100-fold (>1x10⁷ to 1x10⁵ at timepoint 0)

Current antibiotics rarely retain bactericidal activities against nondividing or stationary phase bacterial cells; however, R327 showed remarkable activity against slow-growing bacteria thereby indicating potential antibacterial activity in biofilms

In comparison to ampicillin and ciprofloxacin, R327 is able to outperform both of these antibiotics in bactericidal activity (as measured by viable cell counts) against stationary cells

Bacterial Cell Lysis

  • 00:00 minutes

    Before application of RECCE® 327,
    the E.coli bacteria cells are healthy,
    smooth and intact.

  • 20 minutes

    Atter application of RECCE® 327 ,
    the E.coli bacteria cell membrane
    begins to weaken and is disrupted

  • 180 minutes

    E.coli bacteria cells (10e6 cfu/ml) having their outer membrane weakened and bursting from treatment with RECCE® 327 (1000 ppm)

Electron microscope images generated by Dr Peta Clode and Lyn Kirilak of the Centre for Microscopy, Characterisation and Analysis, University of Western Australia, demonstrate RECCE® 327’s unique mechanism of action.

Previous studies have also indicated R327 to have a unique ability to cause bacterial cell lysis without undue inhibition of healthy cells.

Data indicates RECCE® 327’s mechanism of action to work through:

  • Hydrophobic interactions with the polymer non-specifically attract and bind the antibiotic to proteins of the bacterial plasma membrane.
  • Subsequent disruption of the bacterial cell wall and the high internal pressure in bacteria (up to 10 atmospheres) leads to cell lysis.
  • Non-bacterial (eukaryotic) cells remain intact since they do not contain high internal pressures to result in cell lysis.


RECCE® 529 is a new synthetic polymer formulation with indication against viruses. The Company looks forward to expanding upon this promising indication in due course.

The Company continues to strengthen and expand their product pipeline in order to find a treatment for ‘difficult to treat’ viral infections.

Sign up for news and updates

Receive news and information direct to your inbox.